MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for Alzheimer’s and Parkinson’s diseases.
The article, published in The Scientist and titled “Buntanetap: From Execution Poison to Potential Alzheimer’s Disease Drug,” examines the compound’s historical development and scientific progression, according to the company.
Annovis said buntanetap is currently being evaluated in a Phase 3 clinical trial for early Alzheimer’s disease, with approximately 70% of patients enrolled, and in an open-label extension study for Parkinson’s disease, with about 20% enrollment.
The publication traces the compound’s origins to the 19th century and outlines its development, including identification of its mechanism of action, refinement of its chemical form, and advancement through clinical trials.
The company said the article provides context for its ongoing research as it advances its clinical pipeline.
“Buntanetap is the product of more than a century and a half of pharmacological refinement and clinical learning,” said Alexander Morin, director of strategic communications at Annovis. “This article is an opportunity to share that story in accessible language.”
Annovis is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
The article is available at https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.